Supplementary Figures 1-6, Supplemental Table 1 from Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma

Supplementary Figure S1. ALK copy number data from TCGA-FX-A48G and TCGA-IW-A3M6 LMS visualized using IGV (Broad, MIT) Supplementary Table S1. Identification of ALK rearrangements using ChimeraScan algorithm. Supplementary Figure S2. Results from the fusion analysis pipeline run on RNA-seq data for TCGA-FX-A48G identifying KANK2-ALK Supplementary Figure S3. Results from the fusion analysis pipeline run on RNA-seq data for TCGA-IW-A3M6 identifying ACTG2-ALK Supplementary Figure S4. Confirmation of KANK2-ALK transgene expression from transformed Ba/F3 cells. Supplementary Figure S5. Dose-response inhibitor assay with ALK inhibitors with Ba/F3 parental cells in presence of IL-3 Supplementary Figure S6. Body weight of mice treated with vehicle, crizotinib or lorlatinib